Hi Yamaha,I actually had a line in there mentioning HER-Vaxx - I...

Hi Yamaha,

I actually had a line in there mentioning HER-Vaxx - I agree there could be a deal out of left field there. It's the reason I and many of the long term holders are here. The only reason I didn’t reference it is because it's become a bit of an unknown. The crescendo for HER-Vaxx has arguably past, and since that crescendo, we have seen a few HER-2 therapies get solid results.

I don't believe it's a dead duck though, and im confident something will still be yielded there but in my opinion it pales in comparison to the potential of the rest of the suite of therapies.

Finally, I'd rather set my expectations around seemingly more known milestones for Azer-Cel/CF33/OnCARlytics.

Cheers